港股异动 | 科济药业-B(02171)涨超6% Claudin18.2 CAR-T舒瑞基奥仑赛注射液纳入突破性治疗药物品种

智通财经2025-03-03

智通财经APP获悉，科济药业-B(02171)涨超6%，截至发稿，涨6.14%，报16.94港元，成交额5500.42万港元。消息面上，科济药业今早宣布，公司自主研发的舒瑞基奥仑赛注射液（研发代码：CT041）已被国家药品监督管理局药品审评中心纳入突破性治疗药物品种名单，拟定适应症为既往接受过至少二线治疗失败的Claudin18.2表达阳性的晚期胃/食管胃结合部腺癌。公司预计将于2025年上半年向...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2516872522?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-03-03 09:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2516872522","market":"us","top_or_hot":-1,"title":"港股异动 | 科济药业-B(02171)涨超6% Claudin18.2 CAR-T舒瑞基奥仑赛注射液纳入突破性治疗药物品种","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，科济药业-B(02171)涨超6%，截至发稿，涨6.14%，报16.94港元，成交额5500.42万港元。消息面上，科济药业今早宣布，公司自主研发的舒瑞基奥仑赛注射液（研发代码：CT041）已被国家药品监督管理局药品审评中心纳入突破性治疗药物品种名单，拟定适应症为既往接受过至少二线治疗失败的Claudin18.2表达阳性的晚期胃/食管胃结合部腺癌。公司预计将于2025年上半年向...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1256714.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 科济药业-B(02171)涨超6% Claudin18.2 CAR-T舒瑞基奥仑赛注射液纳入突破性治疗药物品种</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 科济药业-B(02171)涨超6% Claudin18.2 CAR-T舒瑞基奥仑赛注射液纳入突破性治疗药物品种\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-03 09:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1256714.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，科济药业-B(02171)涨超6%，截至发稿，涨6.14%，报16.94港元，成交额5500.42万港元。消息面上，科济药业今早宣布，公司自主研发的舒瑞基奥仑赛注射液（研发代码：CT041）已被国家药品监督管理局药品审评中心纳入突破性治疗药物品种名单，拟定适应症为既往接受过至少二线治疗失败的Claudin18.2表达阳性的晚期胃/食管胃结合部腺癌。公司预计将于2025年上半年向...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1256714.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1256714.html","article_id":"2516872522","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2516872522","pubTimestamp":1740966496,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，科济药业-B涨超6%，截至发稿，涨6.14%，报16.94港元，成交额5500.42万港元。消息面上，科济药业今早宣布，公司自主研发的舒瑞基奥仑赛注射液已被国家药品监督管理局药品审评中心纳入突破性治疗药物品种名单，拟定适应症为既往接受过至少二线治疗失败的Claudin18.2表达阳性的晚期胃/食管胃结合部腺癌。公司预计将于2025年上半年向国家药品监督管理局递交舒瑞基奥仑赛注射液的新药上市申请。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1574":"生物医药B类股","BK4230":"旅客陆运","BK1587":"次新股","BK4022":"陆运","BK1585":"昨日强势股","02171":"科济药业-B","CAR":"安飞士","BK1161":"生物科技"},"translate_title":"Changes in Hong Kong stocks Keji Pharmaceutical-B (02171) rose more than 6% Claudin18.2 CAR-T Shuruiji Orensai injection was included in breakthrough therapeutic drugs","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAR":1,"02171":1},"content_text":"智通财经APP获悉，科济药业-B(02171)涨超6%，截至发稿，涨6.14%，报16.94港元，成交额5500.42万港元。消息面上，科济药业今早宣布，公司自主研发的舒瑞基奥仑赛注射液（研发代码：CT041）已被国家药品监督管理局药品审评中心纳入突破性治疗药物品种名单，拟定适应症为既往接受过至少二线治疗失败的Claudin18.2表达阳性的晚期胃/食管胃结合部腺癌。公司预计将于2025年上半年向国家药品监督管理局递交舒瑞基奥仑赛注射液的新药上市申请。国元国际此前指出，公司是创新研发驱动型生物科技公司，专注于创新CAR-T 细胞疗法，通用型CAR-T 技术领先，治疗实体瘤CAR-T 取得突破，CT041治疗胃癌有望于25 年上半年递交NDA。公司已经有上市产品赛恺泽，由华东医药推广，即将放量。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2516872522","isCrawlerRequest":true}